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ABSTRACT
The analysis of plasma circulating tumour nucleic acids provides a non-invasive 
approach to assess disease burden and the genetic evolution of tumours in response 
to therapy. BRAF splicing variants are known to confer melanoma resistance to BRAF 
inhibitors. We developed a test to screen cell-free RNA (cfRNA) for the presence of 
BRAF splicing variants. Custom droplet digital PCR assays were designed for the 
detection of BRAF splicing variants p61, p55, p48 and p41 and then validated using 
RNA from cell lines carrying these variants. Evaluation of plasma from patients with 
reported objective response to BRAF/MEK inhibition followed by disease progression 
was revealed by increased circulating tumour DNA (ctDNA) in 24 of 38 cases at the 
time of relapse. Circulating BRAF splicing variants were detected in cfRNA from 3 of 
these 38 patients; two patients carried the BRAF p61 variant and one the p55 variant. 
In all three cases the presence of the splicing variant was apparent only at the time of 
progressive disease. BRAF p61 was also detectable in plasma of one of four patients 
with confirmed BRAF splicing variants in their progressing tumours. Isolation and 
analysis of RNA from extracellular vesicles (EV) from resistant cell lines and patient 
plasma demonstrated that BRAF splicing variants are associated with EVs. These 
findings indicate that in addition to plasma ctDNA, RNA carried by EVs can provide 




Mutations in the serine/threonine kinase BRAF 
are found in 40% of melanomas [1]. The most prevalent 
mutation in melanoma is BRAF V600E, which 
constitutively activates downstream mitogen-activated 
protein kinase (MAPK) signalling. Introduction of 
single agent BRAF mutant inhibitors (BRAFi), such 
as vemurafenib and dabrafenib, revolutionised the 
treatment of metastatic melanomas [2, 3]. Furthermore, 
the combination of BRAF and MEK inhibitors (such 
as dabrafenib and trametinib, or vemurafenib and 
cobimetinib) improved tumour response rate and 
progression-free survival, while attenuating some of the 
serious adverse events observed with monotherapy [4, 5]. 
However, even with combination therapies, resistance to 
MAPK inhibition remains a major challenge in clinical 
care, with the majority of patients progressing within 10 
months [6]. Identification of the mechanism of resistance 
to targeted therapies in individual patients may offer new 
insights into strategies for overcoming resistance.
Resistance to BRAF inhibitors usually involves 
MAPK reactivation, via mutations in NRAS or MAP2K1/2, 
upregulation of receptor tyrosine kinases, mutant BRAF 
gene amplification or alternative BRAF splicing [7–
10]. In around 30% of resistant tumours, resistance to 
BRAF inhibition is conferred by alternative splicing via 
generation of BRAF isoforms lacking the RAS binding 
domain (RBD) encoded by exons 3–5 [7, 11]. In the 
absence of the RBD, these BRAF isoforms dimerise even 
in the presence of low levels of RAS, conferring and 
conferring resistance to BRAF inhibition [12]. Four BRAF 
splicing variants, referred to as p61, p55, p48 and p41 
were named based on their predicted molecular weight 
(Figure 1A).
The analysis of tumour-derived biomarkers in 
blood of cancer patients is transforming clinical cancer 
pathology. Circulating tumour DNA (ctDNA) has emerged 
as a non-invasive biomarker to track tumour burden and 
allow monitoring of the cancer genome in blood across 
several malignancies including melanoma [13, 14]. We, 
and others, have previously demonstrated that increased 
melanoma ctDNA levels and the appearance of circulating 
mutations associated with of acquired resistance, provide 
highly specific, early information of relapse during BRAF 
targeted therapies [15, 16]. The latter supports a clinical 
model that incorporates the analysis of ctDNA in patients 
undergoing BRAF-inhibitor therapies as a routine test 
to detect early relapse and resistance [13, 14]. However, 
resistance involving aberrant splicing variants, cannot 
be detected through ctDNA analysis, and can only be 
identified using RNA.
Circulating tumour-derived cell free RNA or 
circulating tumour RNA (ctRNA) can be found in plasma 
from patients with cancer [17–19]. Various studies have 
also demonstrated the ability to amplify tumour-related 
mRNAs from sera of patients with melanoma, breast 
cancer, and other malignancies [20–24]. However, the 
possibility that extracellular RNA could survive in 
the blood has not been widely accepted, due to plasma 
containing potent ribonucleases capable of degrading 
cell-free RNA [25]. Regardless of this, studies have 
documented the presence of ctRNA in serum/plasma of 
cancer patients [26, 27].
Extracellular vesicles (EVs) are known to contain 
various RNA types, including microRNA, mRNA and 
circular RNA [28]. EV RNA has been described as 
having a substantial role in the transfer and movement 
of epigenetic information and is stable enough for whole 
transcriptome sequencing [29–31]. It is plausible that 
plasma cell-free RNA (cfRNA) is a mixture of RNA 
protected by RNA binding proteins and RNA contained 
within EVs. Here we explore whether alternative BRAF 
splicing variants can be detected in melanoma patients 
who have developed resistance to BRAF inhibitor 
therapy. We report a new methodological approach based 
on digital droplet polymerase chain reaction (ddPCR) to 
assess the presence of BRAF splicing variants in plasma 
cfRNA and EV-derived RNA. We interrogated plasma 
from 38 melanoma patients identified as having clinically 
diagnosed treatment resistance after initial response to 
BRAF inhibitor monotherapy or BRAF/MEK inhibitor 
combination. In addition, cfRNA was interrogated 
from an additional five patients who were confirmed 
to have tumour specific BRAF splicing variants in their 
progressing tumours. Finally, we evaluated the presence of 
BRAF splicing variants in EV RNA isolated from plasma 
of two melanoma patients failing BRAF inhibition.
RESULTS
Development of a sensitive assay for detection of 
BRAF splicing variants in plasma
We developed ddPCR assays for the detection 
of alternative BRAF splicing variants: p61, p55, p48 
and p41, which are associated with resistance to BRAF 
inhibition, as well as the canonical full length BRAF 
(pFL) (Figure 1A). The assays were validated using three 
melanoma cell lines with resistance to BRAF inhibition 
and known to express alternative BRAF splicing variants 
(Figure 1B). As previously reported, SK-Mel-28. BR4 
expresses BRAF p55 (exon 4-10∆), SMU027 expresses 
BRAF p48 (exon 2-8∆) and WMD009 expresses 
BRAF p41 (exon 2-10∆) [9, 32]. Surprisingly without 
amplification all cell lines carry the BRAF p61, albeit at 
lower concentrations in comparison to the dominant splice 
variant expressed. Similarly, SMU027 expressed low 
levels of BRAF p41 compared to WMD009.
To enhance sensitivity of detection of BRAF splicing 
variants, a pre-amplification step was introduced. This 
resulted in a significant enhancement of the signal without 
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loss of specificity (Figure 1B). Importantly, the introduced 
pre-amplification step maintained a linear relation between 
copies of input cDNA and output BRAF splicing variant 
copies (R2 = 0.9986, p < 0.0001), with a 6,396 ± 569 fold 
increase in BRAF splicing variant copies (Supplementary 
Figure 2).
We tested plasma from nine healthy volunteers, to 
confirm that the BRAF splicing variants are not commonly 
found in normal plasma and that the assay does not 
introduce artefacts or induce false detection of BRAF 
alternative splicing variants (Supplementary Figure 3).
Analysis of BRAF splicing variants in plasma of 
melanoma patients
We prospectively collected longitudinal plasma 
samples from 38 patients: 7 vemurafenib and 31 dabrafenib/
trametinib treated cases (Supplementary Figure 4). Of the 
7 vemurafenib cases, 2 had baseline plasma for ctDNA 
analysis, and of these 1 experienced a decrease in mutant 
BRAF during treatment (MM143), while the other had 
an increase in mutant BRAF copies during treatment 
(MM141). Of the 31 dabrafenib/trametinib cases, 25 had 
assessable baseline plasma, and of these 24 cases had 
detectable ctDNA (as mutant BRAF copies) at baseline. 
In 19 of the 24 cases, ctDNA decreased during treatment 
in comparison to the baseline sample. Analysis of blood 
samples collected at the time of progressive disease (red 
points – Supplementary Figure 4), identified 29 patients 
(5 on vemurafenib and 24 on combination dabrafenib/
trametinib therapy) with detectable ctDNA at progression. 
Of those, seven had additional NRAS Q61 mutations and 
one had a BRAF gene amplification detectable in plasma 
(Figure 2 and Supplementary Table 1).
Three patients (MM175, MM493 and MM878) had 
detectable BRAF splicing variants in plasma using our 
assay, indicating the presence of ctRNA. BRAF splicing 
variants were not detected in the pre-treatment plasma 
(MM493, MM878) despite clear detectable ctDNA 
(Figure 3). Unfortunately, no plasma collected at baseline 
was available from MM175 for BRAF splicing variant 
assessment.
MM175 presented with multiple spine, rib and liver 
metastases. The patient received dabrafenib/trametinib 
combination treatment and showed a partial response at 5 
weeks, with undetectable ctDNA (Figure 3A). Subsequent 
scans confirmed progression with the patient being 
moved onto ipilimumab immunotherapy. Analysis of 
plasma ctRNA at the final point of dabrafenib/trametinib 
progression (21 weeks) and after change of therapy to 
ipilimumab (38 weeks), revealed that the BRAF splicing 
variant p55 was present only at the time of progression 
but undetectable while on ipilimumab treatment, despite 
having sustained BRAF V600K ctDNA levels.
MM493 presented with multiple brain, lung and 
abdomen metastases. One brain metastasis was resected 
while and the others were treated with whole brain 
radiotherapy. This patient received dabrafenib/trametinib 
combination treatment with partial response at 8 weeks 
and limited decrease in ctDNA (Figure 3B). BRAF p61, 
Figure 1: BRAF splice variants detection by droplet digital PCR. (A) BRAF exon organisation of the splicing variants and 
location of primers and probes used for detection of splicing variants. (B) Droplet digital PCR Ch1,1D plots of each BRAF splicing 
detection assay of melanoma cell lines carrying BRAF splicing variants, with and without the pre-amplification, (PreAmp) step.
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but no other BRAF splicing variants, was detected at 
the time of progression (17 weeks, Figure 3B). Plasma 
collected at baseline, during response (10 weeks) or 
after starting pembrolizumab (25 weeks) did not have 
detectable BRAF splicing variants. BRAF V600E ctDNA 
was detectable in this patient at all four-time points 
analysed but became undetectable by week 54 in response 
to treatment with pembrolizumab.
The third patient (MM878) presented with 
widespread melanoma in lung, lymph node, adrenal, bone 
and gallbladder. The patient was placed on dabrafenib/
trametinib combination treatment and a partial metabolic 
response was observed 5 weeks later which was 
concordant with a decrease from 458 copies/ml to 56 
copies/ml decrease in BRAF V600E ctDNA (Figure 3C). 
At the time of progression additional skeletal metastases 
were observed by PET scan 18 weeks into therapy, with 
ctDNA levels significantly increased to 458 copies/ml, 
with the PET scan confirming progression of several 
skeletal metastases. The BRAF p61 variant was detectable 
in plasma at the point of progression, but was undetectable 
at baseline or the first follow up sample collected 4 weeks 
into therapy (Figure 3C).
To validate our findings, we next tested the plasma 
derived from five melanoma patients that were treated 
with vemurafenib monotherapy who developed resistance. 
Tumour samples obtained at the time of progression had 
confirmed BRAF splicing variants by transcriptome 
analysis [8] (Figure 4). We analysed plasma samples 
from these patients collected near the time of resecting 
the progressed tumour. Only one of these five cases 
(MIA_10) had a detectable splicing variant (BRAF p61) 
in plasma which was concordant with the results of the 
matched tumour sample. BRAF splicing variants were not 
detectable in the baseline plasmas from theses patient.
BRAF splicing variants are associated with 
extracellular vesicles
Plasma extracellular RNAs are thought to be 
carried by extracellular vesicles [33]. To evaluate whether 
BRAF splicing variants are found in EVs, we analysed 
extracellular vesicles extracted from the plasma of patients 
MM493 and MM878. EVs isolated from the supernatant 
of SK-Mel-28. BR4 cell line and from the plasma of a 
healthy control were used as positive and negative 
controls, respectively.
The effective isolation of EVs was confirmed 
by western blot analysis, with positive signal for the 
tetraspanins CD9, CD63, CD81 and Tumour Susceptibility 
Gene 101 (TSG101), while negative for the cellular 
marker calnexin (Figure 5A and Supplementary Figure 5). 
Figure 2: Clinical and ctDNA profile of patients that showed clinical progressive disease to targeted therapy. Overview 
of ctDNA results (copies/mL plasma) from BRAF, NRAS, BRAF splicing and BRAF amplification in 38 melanoma patients. Each column is 
an individual patient, showing their clinical characteristics, quantitative ctDNA results (copies/ml or µl of plasma) and presence of BRAF 
amplification. *BRAF V600E c.1799_1800GT>AA, p. (Val600Glu), also known as BRAF V600E2 mutation.
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Transmission electron microscopy (TEM) was used to 
visualise the extracted EVs, demonstrating the presence 
of exosomes with a size of 100 nm (Figure 5B). Analysis 
of EV RNA from SK-Mel-28. BR4 cells confirmed the 
presence of BRAF p61 and BRAF FL, while EV RNA 
from healthy volunteer only carried BRAF FL variants. 
EV RNA from both MM493 and MM878 contained BRAF 
p61 transcripts (Figure 5C).
DISCUSSION
The emergence of BRAF splicing variants is a 
common mechanism of escape to BRAF inhibition in 
melanoma [10, 12]. Elucidation of the molecular escape 
mechanisms usually requires the sourcing of tumour 
tissue at the time of progressive disease. Here we show 
that tumour specific splicing variants, known to mediate 
treatment resistance, can be detected in plasma.
Our study demonstrated the detection of resistance 
mediating BRAF splicing variants in ctRNA of melanoma 
patients failing BRAF inhibiting therapies. Moreover, we 
showed that these BRAF splicing variants are co-purified 
or associated with EVs.
The frequency at which we detect splicing variants 
in this cohort was low. Tumour analyses within cohorts 
treated with BRAF inhibiting monotherapies suggest a 
prevalence of approximately 30% for splicing variants 
[8, 10]. Long et al. suggested that BRAF splicing were 
unlikely to occur in combination therapy as MAPK 
signalling driven by such variants will require MEK 
activity and therefore will remain sensitive to MEK 
inhibitors [9, 34]. Nevertheless, we did not detect BRAF 
splicing variants in any of the 7 patients treated with 
vemurafenib monotherapy. In contrast, we observed 
BRAF splicing variants in 3 of 31 patients treated with 
combination BRAF/MEK inhibitors. A study by Wagle 
et al., reported the detection of BRAF p41 in the post-
treatment tumour of 1 out of 5 patients that developed 
resistance to dabrafenib/trametinib [35].
In this study, we failed to detect BRAF splicing 
variants in 4 of 5 patients for which the tumours were 
confirmed to carry BRAF splicing variants by tissue 
analysis. The isolation and presence of circulating RNA 
was confirmed in all samples through the presence of 
BRAF full length. Moreover, we showed that our method 
had high analytical sensitivity and specificity. However, 
several technical and biological reasons may explain the 
low clinical sensitivity of the test. Similar to ctDNA, 
ctRNA detection is likely to be affected by tumour 
burden, metabolic activity and location of the tumour [36, 
37]. In addition, pre-analytical conditions have not been 
optimised for the preservation and extraction of ctRNA or 
Figure 3: Detection of splice variants in the combination therapy cohort. Three patients undergoing combination BRAFi 
therapy were positive for a splicing variant. Patients MM175 (A) and patients MM493 (B), were both positive for the p61 variant at the 
point of progressive disease shown in the droplet digital plots. Patient MM878 (C), was positive for the p55 variant also shown in the 
droplet digital plot. The longitudinal graphs represent the ctDNA tracking of the activating mutation for the patients. Red, green and grey 
dotted lines represent clinical response, progressive disease and stable disease respectively. The singular red dot represents the time-
initial point tested positive for the splicing variants and neighbouring time-points were tested to confirm the presence or absence of the 
splicing variants. The coloured area indicates the period during which systemic therapy was administered; colours representing dabrafenib/
trametinib (yellow), ipilimumab (red) and pembrolizumab (blue). Droplet digital plot represents the positivity for the indicated BRAF 
splicing variant (blue dots). BRAF full length (BRAF FL, green dots) was use as positive control for RNA extraction and amplification. No 
template control and positive control (SK-Mel-28. BR4) were included in each test.
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EV-derived mRNA in the same way that it has been done 
for ctDNA [38].
The presence of ctRNA has been previously reported 
in plasma and other body fluids of cancer patients [17, 
39–41]. Early reports published by Lo et al. [42] indicated 
the presence of tumour derived ctRNA in the plasma of 
nasopharyngeal carcinoma patients. Beyond this, ctRNA 
analysis has been expanded primarily into cancer detection 
cancer or monitoring response [43]. For example, plasma 
ctRNA expression of the carcinoembryonic antigen has 
been used for diagnosis of early stage prostate cancer 
[43] and plasma TERT mRNA levels have demonstrated 
to be predictive of response to chemoradiotherapy in 
rectal cancers [44]. Thus, ctRNA shows promise as an 
additional monitoring tool that can be used in combination 
with ctDNA and conventional methods. The advantage of 
ctRNA is implied through the assessment of transcriptional 
activity of genes.
The effective isolation of EVs was validated using 
western blot and transmission electron microscopy. Purity 
was confirmed through negativity of calnexin, along with 
the positivity of CD9, CD63, CD81 or TSG101 which are 
EV associated proteins [45]. Patient MM828-EV sample 
was CD81 negative but positive for the other markers, 
demonstrating that reliance on one or two markers poses a 
risk of false negativity. The heterogeneity of EV-associated 
proteins has been reported previously [46–48], suggesting 
that a panel of markers is required to validate the presence 
of EVs.
EVs have been established as carriers of various 
types of RNA, including mRNA, miRNA and long non-
coding RNAs [49–51]. The EV RNA from the patients 
MM493 and MM878 were found positive for BRAF-p61, 
matching the results obtained via their plasma ctRNA. 
This suggests that ctRNA may be carried totally or 
partially by EVs, and that these vesicles may be protecting 
RNA from degradation [49, 52, 53].
Alterations on splicing variants have been shown 
to be associated with cancer progression and treatment 
resistance [54]. Splicing variants of the androgen receptor, 
in particular AR-V7, have been found to be significantly 
higher in hormone refractory prostate cancer and is 
associated with poor clinical outcomes [55]. Similar to 
BRAF-splicing variants, AR-V7 can be detected in plasma 
EV RNA [53, 56]. Altogether, this supports an alternative 
liquid biopsy modality based on EV RNA or ctRNA.
Figure 4: Detection of BRAF splice variants in patients known to have the splice variant. (A) Patients who had confirmation 
of splicing variants in the tumour were investigated to confirm the presence of the variant in the plasma. (B) The droplet digital plot 
represents the positivity for p61 in one of the samples.
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Liquid biopsies have emerged as a non-invasive 
approach to assess disease burden and the genetic 
evolution of tumours in response to therapy [15, 57–59]. 
Our study provides a foundation for the detection of 
splicing variants in both ctRNA and EV RNA in melanoma 
patients failing MAPK inhibition, although its clinical 
validity requires further evaluation in independent cohorts. 
This work constitutes an important proof of concept that in 
addition to plasma ctDNA, ctRNA can provide important 
tumour specific information related to the development of 
resistance. However pre-analytical conditions for ctRNA 




A total of 38 participants with BRAF mutant 
metastatic melanoma were treated with vemurafenib 
or with dabrafenib and trametinib combination as per 
approved label were enrolled (Supplementary Table 1). 
Patients were required to have a recorded objective 
response to therapy, either partial or complete confirmed 
by CT or PET scans. All patients gave their signed 
informed consent before blood collection and data 
analysis. The study was performed in accordance with 
the Declaration of Helsinki and study protocols were 
approved by the Human Ethics Committees at Edith 
Cowan University (No.11543) and Sir Charles Gardner 
Hospital (No.2013-246).
Plasma from another five patients treated recruited 
at the Melanoma Institute Australia and affiliated hospitals 
were included in this study (Melanoma Institute Australia 
Biospecimen Bank for Melanoma Research ×11-0289 & 
HREC/11/RPAH/444 approved through Sydney Local 
Health District). These patients were selected as they were 
previously identified as to have BRAF splicing variants 
in their progressing tumour after failing treatment with 
dabrafenib monotherapy.
Cell culture
Melanoma cell line 451Lu was obtained from 
the Wistar Institute. SK-Mel-28. BR4, SMU027 and 
WMD009 were previously reported to carry BRAF 
splicing variants [9, 32]. All cell lines were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo 
Fisher Scientific, Carlsbad, CA, USA) supplemented with 
10% Foetal Bovine Serum (Thermo Fisher Scientific, 
Carlsbad, CA, USA) at 37°C and 5% CO2.
RNA extraction from cell lines
RNA was extracted using the All Prep DNA/RNA 
Mini kit (Qiagen, Hilden, Germany) according to the 
Figure 5: Validation of EV isolation from exo-easy and confirmation of splicing variant presence. (A) EVs isolated using 
the ExoEasy Kit were tested for the associated markers TSG-101, CD81, CD9 and CD63 and the negative marker Calnexin. Loading was 
standardised at 4 µg across all EVs preparations. (B) Electron micrographs were used to determine the presence of EV/exosomes in the 
appropriate size range. (C) Droplet digital testing for BRAF p61 (blue dots) and FL-BRAF (green dots) in EV-derived RNA from the 
patients, healthy controls and cell line SK-Mel-28. BR4.
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manufacturer’s instructions. RNA was eluted in RNAse 
free water and stored at –80°C until analysis.
Circulating nucleic acid extraction
Blood samples were collected into EDTA vacutainer 
tubes and plasma was separated within 24 hours by 
centrifugation at 300 g for 20 minutes, followed by a 
second centrifugation at 4700 g for 10 minutes and then 
stored at –80°C until extraction. Plasma cell-free nucleic 
acids (cfNA) were isolated from healthy donors and AJCC 
stage IV metastatic melanoma patients using the QIAamp 
Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany) as 
per the manufacturer’s instructions. cfNA was eluted in 40 µl 
AVE buffer (Qiagen, Hilden, Germany) and stored at –80°C.
Reverse transcription and preamplification
Extracted RNA (5 µl) from all samples were used 
for cDNA preparation using the SuperScript® VILO™ 
cDNA Synthesis Kit (Thermo Fisher Scientific, Carlsbad, 
CA, USA) followed by a preamplification using the 
TaqMan® PreAmp Master Mix Kit (Thermo Fisher 
Scientific, Carlsbad, CA, USA) and all the primers for the 
BRAF splicing variants at 180 nM, following manufacturer 
cycling conditions (95°C for 10 minutes, followed by 14 
cycles of 95°C for 15 seconds and 60°C for 4 minutes, 
with a final inactivation step at 99°C for 10 minutes). 
Linearity of the pre-amplification step was assessed by 
linear regression of a serial dilution curve (Supplementary 
Figure 2).
Droplet digital PCR
Primer pairs were designed to amplify over the 
unique exon-exon junction of each splicing variant, 
with probes overlapping the junction (Figure 1A and 
Supplementary Table 2). Probes were custom synthesised 
by Integrated DNA Technologies (IDT, San Jose, CA, 
USA). For ctDNA analysis, samples were analysed for 
the presence of BRAF or NRAS mutant DNA as described 
previously [15, 60].
Amplifications were performed in a 20 µL reaction 
containing 1× ddPCR Supermix for Probes (No dUTP, Bio-
Rad), 1× Q solution (Qiagen, Hilden, Germany), 250 nM 
of each probe and 900 nM of each primer plus template. 
Droplets were generated using the automatic droplet 
generator QX200 AutoDG (Bio-Rad, Hercules, CA, USA). 
Amplifications were performed using the following cycling 
conditions: 1 cycle of 95°C (2.5C/s ramp) for 10 minutes, 
40 cycles of 94°C (2.5C/s ramp) for 30 seconds and 55°C 
for 1 minute, followed by 1 cycle of 98°C (2.5C/s ramp) 
for 10 minutes. Droplets were analysed through a QX200 
droplet reader (Bio-Rad, Hercules, CA, USA). QuantaSoft 
analysis software (Bio-Rad, Hercules, CA, USA) was used 
to acquire and analyse data.
BRAF amplification analysis
We optimised a ddPCR assay to assess the presence 
of BRAF amplifications using plasma-derived cfDNA. 
BRAF copy number was assessed relative to a reference 
gene situated in the centromere of chromosome 7 (VOPP1 
gene, 7p11.2). For the assessment of BRAF: VOPP1 ratio, 
a ddPCR assay was performed with the Bio-Rad QX200 
system using custom primers/probe sets against BRAF [60] 
and VOPP1 (Bio-Rad, Hercules, CA, USA). The BRAF: 
VOPP1 concentration ratio was determined by dividing the 
BRAF concentration by the VOPP1 concentration offered 
by the QuantaSoft software (Bio-Rad, Hercules, CA, USA).
We first determined the optimal threshold to 
define an elevated plasma DNA ddPCR BRAF: VOPP1 
ratio using a standard curve of genomic DNA extracted 
from healthy volunteer WBC combined with different 
percentages of genomic DNA extracted from a melanoma 
cell line with known BRAF amplification (Supplementary 
Figure 1). Plasma-derived cfDNA from six healthy 
volunteers were used to evaluate specificity. Patient 
samples with mutant BRAF frequency abundance of 3% 
or higher were tested for BRAF amplification.
Extracellular vesicle isolation
For EVs isolation, cell lines at 50% confluence were 
washed three times with PBS and cultured in DMEM 
supplemented with exosome-depleted FBS (Thermo Fisher 
Scientific, Carlsbad, CA, USA) for 18 hours at 37°C and 5% 
CO2. Following this, cell culture media was harvested and 
centrifuged at 300 g for 5 minutes at 4°C. The supernatant 
was then transferred to a clean tube and re-centrifuged at 
2000 g for 20 minutes. Cleared supernatant was used for EV 
isolation using the ExoEasy kit (Qiagen, Hilden, Germany) 
following manufacturer’s instructions. EVs were also 
isolated from 4 ml of plasma from melanoma patients and 
heathy volunteers using the ExoEasy kit (Qiagen) RNA was 
isolated from the extracted EVs using the RNeasy Micro 
Kit (Qiagen, Hilden, Germany) following manufacturer’s 
instructions. RNA was eluted in 14 µL.
Western blots
SK-Mel-28 cell lysate was prepared to be used 
as positive control. Cells were harvested using trypsin 
EDTA (Thermo Fisher Scientific, Carlsbad, CA, USA). 
Cell viability was then determined using trypan blue. 
Cells were then pelleted at 300 g for five minutes, washed 
twice in PBS and lysed with radioimmunoprecipitation 
(RIPA) assay buffer (Sigma-Aldrich, St. Louis, Missouri) 
containing a complete protease inhibitor tablet (Roche, 
Basel, Switzerland). Cell lysates were incubated for 30 
minutes on ice prior to being cleared with a 13,000 g spin 
for five minutes, with the supernatant being transferred 
into a clean tube and stored at –20°C until use.
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EV pellets were resuspended in PBS prior to 
mixing 1:1 with RIPA (Sigma-Aldrich, St. Louis, 
Missouri) supplemented with protease inhibitor cocktail 
(Roche, Basel, Switzerland). EV lysates were incubated 
for 30 minutes on ice and then stored at –20°C until use. 
Extracted EV proteins were diluted to 1:4 in Lamelli 
Buffer (Bio-Rad, Australia), incubated at 95°C for 
5 minutes and resolved on a mini TGX 8–16% stain 
free gel (Bio-Rad). Proteins were transferred onto a 
nitrocellulose blotting membrane using the Trans-
Blot® Turbo™ Transfer System at a constant voltage 
of 25V for seven minutes (Bio-Rad, Australia). The 
membranes were blocked in 5% milk tris buffered 
saline (TBS) for one hour at room temperature before 
being probed with primary antibody TSG101 (1:1000, 
clone EPR7130B, Abcam), CD9 (1:500, clone 
MM2/57, Life-Technologies), CD81 (1:500, clone 
1.3.3.22, Life-Technologies). CD63 (1:1000, clone 
H5C6, BD-Biosciences, calnexin (1:500, clone AF18, 
Life-Technologies) diluted in 0.5% milk TBS 0.05% 
Tween 20. The membrane was washed three times for 
ten minutes with TBS 0.05% tween and subsequently 
probed with secondary antibodies (sheep anti-mouse 
IgG-HRP conjugate, polyclonal, 1:2000, GE Healthcare, 
donkey anti-rabbit IgG-HRP conjugate, polyclonal, 
1:2000, GE Healthcare) diluted in 0.5% milk TBS .05% 
Tween 20. Signals were detected with the GE healthcare 
Amersham™ ECL™ reagent and were subsequently 
imaged using the ChemiDoc™ Touch Imaging System 
(Bio-Rad, Hercules, CA, USA). Images were processed 
using Image Lab™ software v6.0 (Bio-Rad, Hercules, 
CA, USA).
Transmission electron microscopy
EVs were resuspended in PBS and fixed in 2% 
paraformaldehyde prior to transfer onto 200 mesh 
Formvar-carbon coated copper grids (ProSciTech, 
Kirwan, QLD). EVs were adsorbed for 15 minutes at room 
temperature prior to being washed four times in filtered 
H2O. Samples were then fixed in 1% glutaraldehyde and 
contrasted with 1% uranyl acetate for 2 minutes before 
being left for 20 minutes to dry at room temperature. 
EVs were visualised using JEOL JEM-2100 electron 
microscope (JEOL, Tokyo, Japan) at an operating voltage 
of 80 kV. Images were captured using an 11M pixel Gatan 
Orius digital camera (Gatan, Pleasanton, CA, USA).
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